Paper Details

  1. Home
  2. Paper Details

Low doses of TRH in amyotrophic lateral sclerosis and in other neurological diseases.

Author: CongiaS, CoppolaG, LeddaM, PorcellaA, TronciS

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

This study evaluated the effects of low-dose thyrotropin-releasing hormone (TRH) treatment in 30 patients with various neurological conditions, including amyotrophic lateral sclerosis (ALS), Charcot-Marie Tooth atrophy, and spinal muscular atrophy. TRH treatment resulted in significant neurological improvement in 17 out of 23 patients with ALS, but showed little or no improvement in other patients with ALS or other neurological diseases. This suggests that TRH may be a potential treatment for some patients with ALS.
Paper Details　
Original Abstract of the Article :
30 subjects--23 with amyotrophic lateral sclerosis (ALS), 4 with Charcot-Marie Tooth atrophy, 2 with progressive spinal muscle atrophy and 1 with radiation myelopathy--were given chronic low-dose TRH therapy. The effects of treatment were assessed on the scale of Norris et al. (1974). The outcome of...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1007/BF02337033

データ提供：米国国立医学図書館（NLM）

TRH: A Potential Oasis in the Desert of Neurological Diseases

The field of [neurology] is constantly seeking new avenues to treat debilitating conditions like [amyotrophic lateral sclerosis (ALS)]. This study investigates the potential therapeutic effects of [thyrotropin-releasing hormone (TRH)] in a diverse group of neurological patients. The study employed a [clinical trial] design, administering low-dose TRH to a group of patients with various neurological conditions. The researchers discovered that TRH led to statistically significant neurological improvement in a portion of the ALS patients, providing a glimmer of hope for this challenging disease. While the results were encouraging for some, the study also highlighted the need for further research to understand the specific mechanisms of TRH's action and identify patients who would benefit most from this treatment.

TRH: A Potential Light in the Darkness

The results of this study suggest that low-dose TRH may have therapeutic potential for a subset of ALS patients. Although further research is needed to confirm this finding and determine the optimal treatment regimen, these results offer hope for individuals battling this debilitating disease. The study also highlights the importance of individualized treatment approaches in neurology, recognizing that different patients may respond differently to the same treatment.

Navigating the Complexities of Neurological Disease

The search for effective treatments for neurological diseases like ALS is an ongoing journey. This study underscores the importance of exploring novel therapeutic approaches, while acknowledging the need for rigorous research to establish the safety and efficacy of these treatments. The study also emphasizes the importance of considering individual patient characteristics when developing treatment strategies.

Dr.Camel's Conclusion

In the vast desert of neurological diseases, researchers are constantly searching for oases of hope. This study suggests that TRH may be a potential oasis for some ALS patients, but further exploration is needed to unlock its full potential. Just as a camel adapts to the challenging desert environment, scientists are working to tailor treatments to the unique needs of each individual.

Date :
  1. Date Completed 1991-08-20
  2. Date Revised 2020-03-04
Further Info :

Pubmed ID

1906441

DOI: Digital Object Identifier

10.1007/BF02337033

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.